Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice

Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study

(2018) Courtney D DiNardo et al.   LANCET ONCOLOGY

A concise review of BCL-2 inhibition in acute myeloid leukemia

(2018) Meera Yogarajah et al.   Expert Review of Hematology

From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors

(2017) Avi Ashkenazi et al.   NATURE REVIEWS DRUG DISCOVERY

Targeted therapies in Acute Myeloid Leukemia: a focus on FLT-3 inhibitors and ABT199

(2017) Kiran Naqvi et al.   Expert Review of Hematology

Acute myeloid leukemia: 2016 Update on risk-stratification and management

(2016) Elihu Estey   AMERICAN JOURNAL OF HEMATOLOGY

Directly targeting the mitochondrial pathway of apoptosis for cancer therapy using BH3 mimetics - recent successes, current challenges and future promise

(2016) Kristopher A. Sarosiek et al.   FEBS Journal

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

(2016) András Kotschy et al.   NATURE

The molecular mechanics of mixed lineage leukemia

(2016) R K Slany   ONCOGENE

Impact of loss of BH3-only proteins on the development and treatment of MLL-fusion gene-driven AML in mice

(2016) Rebecca A Bilardi et al.   Cell Death & Disease

The role of the proteasome in AML

(2016) C M Csizmar et al.   Blood Cancer Journal

Efficacy and Biological Correlates of Response in a Phase II Study of Venetoclax Monotherapy in Patients with Acute Myelogenous Leukemia

(2016) M. Konopleva et al.   Cancer Discovery

Acute myeloid leukaemia

(2016) Asim Khwaja et al.   Nature Reviews Disease Primers

Exploiting selective BCL-2 family inhibitors to dissect cell survival dependencies and define improved strategies for cancer therapy

(2015) Joel D. Leverson et al.   Science Translational Medicine

Acute myeloid leukemia cells harboring MLL fusion genes or with the acute promyelocytic leukemia phenotype are sensitive to the Bcl-2-selective inhibitor ABT-199

(2014) X Niu et al.   LEUKEMIA

Discovery of a Potent and Selective BCL-XL Inhibitor with in Vivo Activity

(2014) Zhi-Fu Tao et al.   ACS Medicinal Chemistry Letters

ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia

(2013) C. J. Vandenberg et al.   BLOOD

Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription

(2013) D. Thomas et al.   BLOOD

MDM2 Small-Molecule Antagonist RG7112 Activates p53 Signaling and Regresses Human Tumors in Preclinical Cancer Models

(2013) C. Tovar et al.   CANCER RESEARCH

Loss of MCL-1 leads to impaired autophagy and rapid development of heart failure

(2013) R. L. Thomas et al.   GENES & DEVELOPMENT

Structure-guided design of a selective BCL-XL inhibitor

(2013) Guillaume Lessene et al.   Nature Chemical Biology

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

(2013) Andrew J Souers et al.   NATURE MEDICINE

Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid Leukemia

(2013)   NEW ENGLAND JOURNAL OF MEDICINE

High-Dose Cytarabine (HD araC) in the Treatment of Leukemias: a Review

(2013) Nicholas D. Reese et al.   Current Hematologic Malignancy Reports

Inhibition of apoptosis by BCL2 prevents leukemic transformation of a murine myelodysplastic syndrome

(2012) C. I. Slape et al.   BLOOD

Elevated Mcl-1 inhibits thymocyte apoptosis and alters thymic selection

(2012) K J Campbell et al.   CELL DEATH AND DIFFERENTIATION

Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia

(2012) S. P. Glaser et al.   GENES & DEVELOPMENT

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1

(2010) D. Yecies et al.   BLOOD

Elevated Mcl-1 perturbs lymphopoiesis, promotes transformation of hematopoietic stem/progenitor cells, and enhances drug resistance

(2010) K. J. Campbell et al.   BLOOD

Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia

(2010) Zhifu Xiang et al.   JOURNAL OF CLINICAL INVESTIGATION

Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia

(2009) Rong Chen et al.   BLOOD

Knockout of myeloid cell leukemia-1 induces liver damage and increases apoptosis susceptibility of murine hepatocytes

(2008) Binje Vick et al.   HEPATOLOGY

Mcl-1 Is a Key Regulator of Apoptosis during CNS Development and after DNA Damage

(2008) N. Arbour et al.   JOURNAL OF NEUROSCIENCE